HBM Healthcare
Swiss listed healthcare investment company; participant in CellCentric's £170m Series D.
Last refreshed: 13 May 2026
Timeline for HBM Healthcare
CellCentric raises Europe's largest 2026 biotech round
UK Startups and Innovation- What is HBM Healthcare Investments?
- HBM Healthcare Investments is a Swiss listed investment company (SIX Swiss Exchange) founded in 2001, investing in private and public clinical-stage biotech companies across Europe and the US.Source: HBM Healthcare
- Which Swiss investors backed CellCentric's European biotech round?
- HBM Healthcare Investments, listed on the SIX Swiss Exchange, participated in CellCentric's £170m Series D alongside Venrock Healthcare, Pfizer, and Fidelity.Source: Lowdown uk-startups-and-innovation U#4
Background
HBM Healthcare Investments participated in CellCentric's £170m Series D in May 2026, alongside Venrock Healthcare, Pfizer, Fidelity, Sofinnova Partners, and others. CellCentric's inobrodib programme for multiple myeloma and prostate cancer sits within HBM's clinical-stage oncology focus.
HBM Healthcare Investments is a Swiss investment company listed on the SIX Swiss Exchange, founded in 2001 and headquartered in Zug, Switzerland. It invests in private and public healthcare and biotech companies at clinical stage, with a diversified portfolio across Europe and the US. As a listed closed-end vehicle, HBM provides retail and institutional investors access to a diversified portfolio of clinical-stage biotech companies. Its co-investment in CellCentric alongside institutional VCs and a pharma strategic (Pfizer) signals confidence in the clinical trajectory toward a major trial readout.